NYSE: VTR · Healthcare Facility REITs
Ventas (VTR) fair value and price range
As of 1 Oct 2026, Faircurve's model values Ventas (VTR) at $42.67 a share. The stock last closed at $84.01, which puts the model's fair value 49.2% below the price. No verdict is shown for VTR on this run. The fair value and its range are shown for reference.
Revalued . Price is the close of 2 Oct 2026. Ventas, Inc.
Faircurve Insights · 1 Oct 2026
Ventas, Inc. is an S&P 500 company enabling exceptional environments that benefit a large and growing aging population. It has approximately 1,450 properties in North America and the United Kingdom.
On 1 Oct 2026, Faircurve's model found a fair value of $42.67 a share. This was up 0.4% from the previous run on 26 Sep 2026, which gave $42.50. The model's calibrated range over 63 trading days was $35.80 to $52.03 and held the price 60% of the time at this horizon. The model gave a High evidence grade for Ventas, Inc.
The model compared Ventas, Inc. with Healthpeak Properties, Inc., Omega Healthcare Investors, Inc., American Healthcare REIT, Inc., Welltower Inc., CareTrust REIT, Inc., Healthcare Realty Trust Incorporated, Sabra Health Care REIT, Inc., and LTC Properties, Inc. Moves around the last 8 earnings reports ranged from -6.3% to +9.0%, with a median size of 5.7%.
Written from the figures on this page for the 1 Oct 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give VTR?
The calibrated range for VTR over 63 trading days is $35.80 to $52.03. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,327 past valuations, refreshed 26 Sep 2026). Ranges built this way held the price 60% of the time at this horizon.
The price is above this range. For names with fair value 15%+ below price, the calibrated range has held the price 40% of the time over 63 trading days, and 58% ended above it; the typical move was −0.1%.
The model's own range is $39.35 to $46.55.
How does VTR compare with similar companies?
The companies in healthcare facility reits closest to Ventas in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| DOC Healthpeak Properties, Inc. | $19.49 | $24.21 | +24.2% | Low evidence grade |
| OHI Omega Healthcare Investors, Inc. | $45.72 | $53.51 | +17.0% | No verdict on this run |
| AHR American Healthcare REIT, Inc. | $50.75 | $23.10 | -54.5% | Low evidence grade |
| WELL Welltower Inc. | $227.85 | $60.96 | -73.2% | Gap wider than 60% |
| CTRE CareTrust REIT, Inc. | $36.30 | $31.40 | -13.5% | No verdict on this run |
| HR Healthcare Realty Trust Incorporated | $17.47 | $16.25 | -7.0% | No verdict on this run |
| SBRA Sabra Health Care REIT, Inc. | $19.16 | $16.29 | -15.0% | No verdict on this run |
| LTC LTC Properties, Inc. | $43.00 | $43.30 | +0.7% | Low evidence grade |
All healthcare facility reit stocks ranked by gap to fair value
When does VTR report earnings, and how has the stock reacted?
Ventas's next earnings report is scheduled for 28 Oct 2026. Companies can move their dates.
Options prices on 2 Oct 2026 imply a move of about 8.1% in either direction through the nearest expiry, about 48 days out, a window that includes the report. That is the size the market is pricing, not a direction.
How VTR moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 5.7%.
| Report date | Two session move |
|---|---|
| 29 Jul 2026 | -6.3% |
| 27 Apr 2026 | +4.7% |
| 5 Feb 2026 | +6.2% |
| 29 Oct 2025 | +6.2% |
| 30 Jul 2025 | +0.5% |
| 30 Apr 2025 | -5.2% |
| 12 Feb 2025 | +9.0% |
| 30 Oct 2024 | -0.8% |
Ventas at a glance
Ventas, Inc. is an S&P 500 company enabling exceptional environments that benefit a large and growing aging population. With approximately 1,450 properties in North America and the United Kingdom, Ventas occupies an essential role in the longevity economy.
- Market value
- $42.1B
- Sector
- Real Estate
- Industry
- Healthcare Facility REITs
- Beta to the US market
- -0.12
- First valued by Faircurve
- 4 Jul 2026
How the fair value is worked out: the model values Ventas three ways and blends them; the range around the fair value comes from 2,000 simulations of the dividend model. The full method is documented here.
What changed in the latest valuation?
On 26 Sep 2026 the model's fair value for VTR was $42.50. As of 1 Oct 2026 it is $42.67, a change of +0.4%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Ventas's valuation
Is Ventas stock undervalued or overvalued?
Faircurve's model puts VTR's fair value at $42.67 a share against a last close of $84.01, as of 1 Oct 2026. No verdict is shown for VTR on this run. The fair value and its range are shown for reference.
What is VTR's fair value?
$42.67 a share as of 1 Oct 2026. The fair value blends three methods: a cash-flow multiple against comparable companies, a dividend model, and the value of the properties. The model's own range is $39.35 to $46.55.
What price range does the model give VTR?
$35.80 to $52.03 over 63 trading days. Ranges built this way held the price 60% of the time across 4,327 past valuations, refreshed 26 Sep 2026.
When does Ventas report earnings next?
The next report is scheduled for 28 Oct 2026. Companies can move their dates.
How much has VTR moved on past earnings reports?
Across its last 8 reports the median two session move was 5.7%, ignoring direction. The largest was +9.0% around the report of 12 Feb 2025.
How confident is the model in this valuation?
The model's evidence grade for VTR is high. For real estate investment trusts (REITs) the grade looks at the dividend record: at least three years of paid dividends with no cut. It is not a probability that the fair value is right, or that the price reaches it.